Alan F. List, MD

Dr. Alan List is the president and CEO of Moffitt Cancer Center. He is a senior member in the Department of Malignant Hematology and the Experimental Therapeutics Program. In addition, Dr. List is a professor of internal medicine and oncology at the University of South Florida Morsani College of Medicine. After earning his medical degree from the University of Pennsylvania, Dr. List completed a residency in medicine at Good Samaritan Medical Center in Phoenix, AZ. He pursued fellowships in hematology and medical oncology at Vanderbilt University Medical Center in Nashville, Tenn. Prior to joining Moffitt in 2003, Dr. List was a professor of medicine and director of the Leukemia and Bone Marrow Transplant Program at the University of Arizona Tucson, as well as Associated Center Director of the Division of Translational/Clinical Research. Dr. List is internationally recognized for his many contributions in the development of novel, more effective treatment strategies for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). His pioneering work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical trials, which went on to receive fast-track designation from the U.S. Food and Drug Administration and approval for the treatment of patients with MDS and multiple myeloma. This work transformed the natural history of MDS with chromosome 5q deletion from a malignancy requiring frequent red blood cell transfusions that may progress to acute leukemia to a condition whose blood production normalizes and can be managed in the outpatient setting with an oral agent. Dr. List receives peer-reviewed NIH support for his work and publishes extensively in the areas of MDS and acute leukemia. He lectures nationally and internationally and has received several awards in recognition of his seminal contributions such as induction into The Joshua Lederberg Society; the Emil J. Freireich Award for Clinical Research, M.D. Anderson (2006); the J.P. McCarthy International Prize for Advancing the Body of Scientific Knowledge in Myelodysplastic Syndrome (2004); the General Motors Cancer Research Foundation Merit Award (1991); and the National Academy of Inventors (Charter Fellow, 2013), and the Leadership in Science Award (2014) from the Aplastic Anemia and MDS International Foundation (AA&MDSIF). He is the author of more than 330 peer-reviewed articles and co-editor of Wintrobe’s textbook of Hematology. He serves as a member of the Board of Directors of the Myelodysplastic Syndrome Foundation and the AA & MDS International Foundation, and is the President-Elect (2017-18) for the Society of Hematologic Oncology (SOHO). He also is an active member of the American Society of Clinical Oncology; American Society of Hematology; American Association for Cancer Research; International Society for Experimental Hematology; J.P. McCarthy Foundation Medical Advisory Committee; and the Southwestern Oncology Group.

Provider

Alan F. List, MD
President and CEO

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Malignant Hematology

Print Print Physician Bio

Education & Training

BOARD CERTIFICATION:
  • Hematology
  • Medical Oncology
FELLOWSHIP:
  • Vanderbilt University Medical Center, Nashville, TN - Oncology
  • Vanderbilt University Medical Center, Nashville, TN - Hematology
RESIDENCY:
  • Good Samaritan Medical Center, Phoenix, AZ - Internal Medicine
MEDICAL SCHOOL:
  • University of Pennsylvania - MD
Provider

Alan F. List, MD
President and CEO

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Malignant Hematology

Print Print Physician Bio

Publications

  • Griffin PT, Komrokji RS, Sweet K, Al Ali NH, Padron E, Kubal TE, List AF, Lancet JE. Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience. Am J Hematol. 2017 Mar;92(3):232-237. Pubmedid: 28006850.
  • Sallman DA, Komrokji R, List A, Padron E. Reply to Goel et al. 'TP53 mutation allele-burden and disease outcome in MDS/AML'. Leukemia. 2017 Mar;31(3):767-768. Pubmedid: 27740632.
  • Hosono N, Makishima H, Mahfouz R, Przychodzen B, Yoshida K, Jerez A, LaFramboise T, Polprasert C, Clemente MJ, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, Cui E, Verma AK, McDevitt MA, List AF, Saunthararajah Y, Sekeres MA, Boultwood J, Ogawa S, Maciejewski JP. Recurrent genetic defects on chromosome 5q in myeloid neoplasms. Oncotarget. 2017 Jan;8(4):6483-6495. Pubmedid: 28031539.
  • Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 2017 Jan;18(1):112-121. Pubmedid: 27927582.
  • Almeida A, Fenaux P, List AF, Raza A, Platzbecker U, Santini V. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). Leuk Res. 2017 Jan;52:50-57. Pubmedid: 27883945.
  • Apuri S, Al Ali N, Padron E, Lancet JE, List AF, Komrokji RS. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2017 Jan. Pubmedid: 28185797.
  • Talati C, Zhang L, Shaheen G, Kuykendall A, Ball M, Zhang Q, Lancet JE, Zuckerman KS, List AF, Komrokji R, Moscinski L, Padron E. Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis. Blood. 2017 Feb. Pubmedid: 28159734.
  • Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, Steensma DP, DeZern A, Roboz G, Jabbour E, Garcia-Manero G, List A, Komrokji R. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia. 2017 Feb. Pubmedid: 28111463.
  • Coombs CC, Sallman DA, Devlin SM, Dixit S, Mohanty A, Knapp K, Al Ali NH, Lancet JE, List AF, Komrokji RS, Padron E, Arcila ME, Klimek VM, van den Brink MR, Tallman MS, Levine RL, Rampal RK, Rapaport F. Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. Haematologica. 2016 Nov;101(11):e457-e460. Pubmedid: 27418649.
  • Ball M, List AF, Padron E. When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia. Blood. 2016 Nov;128(20):2381-2387. Pubmedid: 27707735.
  • Scholma J, Fuhler GM, Joore J, Hulsman M, Schivo S, List AF, Reinders MJ, Peppelenbosch MP, Post JN. Improved intra-array and interarray normalization of peptide microarray phosphorylation for phosphorylome and kinome profiling by rational selection of relevant spots. Sci Rep. 2016 May;6:26695. Pubmedid: 27225531. Pmcid: PMC4881024.
  • Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, Craig BM, Padron E, Zhang L, Lancet JE, Pinilla-Ibarz J, List AF, Mufti GJ, Epling-Burnette PK. Autoimmune diseases and myelodysplastic syndromes. Am J Hematol. 2016 May;91(5):E280-E283. Pubmedid: 26875020.
  • Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL, Al Ali NH, Lancet J, McGinniss MJ, Nahas S, Smith AE, Kulasekararaj A, Mufti G, List A, Hall J, Padron E. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. 2016 Mar;30(3):666-673. Pubmedid: 26514544.
  • Abel GA, Efficace F, Buckstein RJ, Tinsley S, Jurcic JG, Martins Y, Steensma DP, Watts CD, Raza A, Lee SJ, List AF, Klaassen RJ. Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematologica. 2016 Jun;101(6):781-788. Pubmedid: 26944474. Pmcid: PMC5013948.
  • Basiorka AA, McGraw KL, De Ceuninck L, Griner LN, Zhang L, Clark JA, Caceres G, Sokol L, Komrokji RS, Reuther GW, Wei S, Tavernier J, List AF. Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41. Cancer Res. 2016 Jun;76(12):3531-3540. Pubmedid: 27197154. Pmcid: PMC4911265.
  • Nazha A, Komrokji RS, Garcia-Manero G, Barnard J, Roboz GJ, Steensma DP, DeZern AE, Zell K, Zimmerman C, Al Ali N, Jabbour E, Greenberg MD, Kantarjian HM, Maciejewski JP, List AF, Sekeres MA. The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica. 2016 Jun;101(6):e224-e227. Pubmedid: 26992944. Pmcid: PMC5013943.
  • Rollison DE, Shain KH, Lee JH, Hampras SS, Fulp W, Fisher K, Al Ali NH, Padron E, Lancet J, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Dalton W, List A, Komrokji RS. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide. Cancer Med. 2016 Jul;5(7):1694-1701. Pubmedid: 27098006. Pmcid: PMC4944897.
  • Komrokji RS, List AF. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes. Ann Oncol. 2016 Jan;27(1):62-68. Pubmedid: 26504152. Pmcid: PMC4684154.
  • Nazha A, Sekeres MA, Garcia-Manero G, Barnard J, Al Ali NH, Roboz GJ, Steensma DP, DeZern AE, Zimmerman C, Jabbour EJ, Zell K, List AF, Kantarjian HM, Maciejewski JP, Komrokji RS. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leuk Res. 2016 Feb;41:43-47. Pubmedid: 26777537. Pmcid: PMC4986515.
  • Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood. 2016 Dec;128(25):2960-2975. Pubmedid: 27737891. Pmcid: PMC5179338.
  • Zhang L, McGraw KL, Sallman DA, List AF. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications. Leuk Lymphoma. 2016 Dec;1-14. Pubmedid: 27967292.
  • Negoro E, Radivoyevitch T, Polprasert C, Adema V, Hosono N, Makishima H, Przychodzen B, Hirsch C, Clemente MJ, Nazha A, Santini V, McGraw KL, List AF, Sole F, Sekeres MA, Maciejewski JP. Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. Leukemia. 2016 Dec;30(12):2405-2409. Pubmedid: 27560106. Pmcid: PMC5143200.
  • List AF, Kantarjian H, Freireich EJ. Proceedings of the Third Annual Meeting of the Society of Hematologic Oncology. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S1. Pubmedid: 27521304.
  • Padron E, Dezern A, Andrade-Campos M, Vaddi K, Scherle P, Zhang Q, Ma Y, Balasis ME, Tinsley S, Ramadan H, Zimmerman C, Steensma DP, Roboz GJ, Lancet JE, List AF, Sekeres MA, Komrokji RS. A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). Clin Cancer Res. 2016 Aug;22(15):3746-3754. Pubmedid: 26858309. Pmcid: PMC5278764.
  • Ramadan H, Duong VH, Al Ali N, Padron E, Zhang L, Lancet JE, List AF, Komrokji RS. Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S64-S66. Pubmedid: 27521328.
  • McGraw KL, Nguyen J, Komrokji RS, Sallman D, Al Ali NH, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica. 2016 Aug;101(8):e320-e323. Pubmedid: 27081179. Pmcid: PMC4967580.
  • Haider M, Al Ali N, Padron E, Epling-Burnette P, Lancet J, List A, Komrokji R. Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S44-S48. Pubmedid: 27521323.
  • Grabska J, Shah B, Reed D, Al Ali N, Padron E, Ramadan H, Lancet J, List A, Komrokji R. Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S53-S56. Pubmedid: 27521325.
  • Zhang X, Sokol L, Bennett JM, Moscinski LC, List A, Zhang L. T-cell large granular lymphocyte proliferation in myelodysplastic syndromes: Clinicopathological features and prognostic significance. Leuk Res. 2016 Apr;43:18-23. Pubmedid: 26927701.
  • Sallman DA, Cluzeau T, Basiorka AA, List A. Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype. Front Oncol. 2016;6:151. Pubmedid: 27379212. Pmcid: PMC4909736.
  • Griffin PT, Komrokji RS, DeCastro CM, Rizzieri DA, Melchert M, List AF, Lancet JE. A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy. Am J Hematol. 2015 Sep;90(9):796-799. Pubmedid: 26089240.
  • Mughal TI, Cross NC, Padron E, Tiu RV, Savona M, Malcovati L, Tibes R, Komrokji RS, Kiladjian JJ, Garcia-Manero G, Orazi A, Mesa R, Maciejewski JP, Fenaux P, Itzykson R, Mufti G, Solary E, List AF. An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica. 2015 Sep;100(9):1117-1130. Pubmedid: 26341525. Pmcid: PMC4800699.
  • McGraw KL, Cluzeau T, Sallman DA, Basiorka AA, Irvine BA, Zhang L, Epling-Burnette PK, Rollison DE, Mallo M, Sokol L, Solé F, Maciejewski J, List AF. TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes. Oncotarget. 2015 Oct;6(33):34437-34445. Pubmedid: 26416416. Pmcid: PMC4741464.
  • Nishihori T, El-Asmar J, Shah B, Hussaini M, Komrokji R, List A, Anasetti C, Kharfan-Dabaja MA. Donor-derived constitutional chromosomal abnormalities after allogeneic hematopoietic cell transplantation: a single-center experience and a review of the literature. Bone Marrow Transplant. 2015 Oct;50(10):1388-1392. Pubmedid: 26191951.
  • Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, Dezern A, Maciejewski JP, List AF, Komrokji RS. Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?. Am J Hematol. 2015 Nov;90(11):1036-1040. Pubmedid: 26284571.
  • Sundaravel S, Duggan R, Bhagat T, Ebenezer DL, Liu H, Yu Y, Bartenstein M, Unnikrishnan M, Karmakar S, Liu TC, Torregroza I, Quenon T, Anastasi J, McGraw KL, Pellagatti A, Boultwood J, Yajnik V, Artz A, Le Beau MM, Steidl U, List AF, Evans T, Verma A, Wickrema A. Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes. Proc Natl Acad Sci U S A. 2015 Nov;112(46):E6359-E6368. Pubmedid: 26578796. Pmcid: PMC4655581.
  • Zeidan AM, Al Ali NH, Padron E, Lancet J, List A, Komrokji RS. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine. Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):705-710. Pubmedid: 26440749.
  • McGraw KL, Zhang LM, Rollison DE, Basiorka AA, Fulp W, Rawal B, Jerez A, Billingsley DL, Lin HY, Kurtin SE, Yoder S, Zhang Y, Guinta K, Mallo M, Solé F, Calasanz MJ, Cervera J, Such E, González T, Nevill TJ, Haferlach T, Smith AE, Kulasekararaj A, Mufti G, Karsan A, Maciejewski JP, Sokol L, Epling-Burnette PK, Wei S, List AF. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes. Blood Cancer J. 2015 Mar;5:e291. Pubmedid: 25768405. Pmcid: PMC4382654.
  • Garcia-Manero G, Khoury HJ, Jabbour E, Lancet JE, Winski SL, Cable L, Rush S, Maloney L, Hogeland G, Ptaszynski M, List AF, Kantarjian H, Komrokji RS. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin Cancer Res. 2015 Mar;21(5):985-994. Pubmedid: 25480830. Pmcid: PMC4348327.
  • Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, Kiladjian JJ, Padron E, Solary E, Tibes R, Itzykson R, Cazzola M, Mesa R, Maciejewski J, Fenaux P, Garcia-Manero G, Gerds A, Sanz G, Niemeyer CM, Cervantes F, Germing U, Cross NC, List AF. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood. 2015 Mar;125(12):1857-1865. Pubmedid: 25624319. Pmcid: PMC4915792.
  • Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer. 2015 Mar;121(6):876-882. Pubmedid: 25410759. Pmcid: PMC4378905.
  • Komrokji R, Ramadan H, Al Ali N, Corrales-Yepez M, Zhang L, Padron E, Lancet J, List A. Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S60-S63. Pubmedid: 26297280.
  • Brayer J, Lancet JE, Powers J, List A, Balducci L, Komrokji R, Pinilla-Ibarz J. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides. Am J Hematol. 2015 Jul;90(7):602-607. Pubmedid: 25802083. Pmcid: PMC4617516.
  • Mishra A, Rollison DE, Brandon TH, Al Ali NH, Corrales-Yepez M, Padron E, Epling-Burnette PK, Lancet JE, List AF, Komrokji RS. Impact of tobacco usage on disease outcome in myelodysplastic syndromes. Leuk Res. 2015 Jul;39(7):673-678. Pubmedid: 25934048.
  • Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH, Thompson Z, Colla S, Fenaux P, Kantarjian HM, Killick S, Sekeres MA, List AF, Onida F, Komrokji RS, Tefferi A, Solary E. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015 Jul;5:e333. Pubmedid: 26230957. Pmcid: PMC4526779.
  • List AF, Bennett JM, Sekeres MA, Skikne B, Fu T, Shammo JM, Nimer SD, Knight RD, Giagounidis A. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. Leukemia. 2015 Dec;29(12):2452. Pubmedid: 26648407.
  • Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, Dezern A, Maciejewski JP, List AF, Komrokji RS. Comparing the Prognostic Value of Risk stratifying Models for Patients with Lower-Risk Myelodysplastic Syndromes: Is one model better?. Am J Hematol. 2015 Aug. Pubmedid: 26260295. Pmcid: PMC4751065.
  • Ostronoff F, Othus M, Lazenby M, Estey E, Appelbaum FR, Evans A, Godwin J, Gilkes A, Kopecky KJ, Burnett A, List AF, Fang M, Oehler VG, Petersdorf SH, Pogosova-Agadjanyan EL, Radich JP, Willman CL, Meshinchi S, Stirewalt DL. Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. J Clin Oncol. 2015 Apr;33(10):1157-1164. Pubmedid: 25713434. Pmcid: PMC4372852.
  • Duong VH, Komrokji RS, List AF. Update on the pharmacotherapy for myelodysplastic syndromes. Expert Opin Pharmacother. 2014 Sep;15(13):1811-1825. Pubmedid: 25080144.
  • Advani AS, McDonough S, Copelan E, Willman C, Mulford DA, List AF, Sekeres MA, Othus M, Appelbaum FR. SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. Brit J Haematol. 2014 Oct;167(2):233-237. Pubmedid: 25039477. Pmcid: PMC4188732.
  • McLornan DP, List A, Mufti GJ. Applying synthetic lethality for the selective targeting of cancer. N Engl J Med. 2014 Oct;371(18):1725-1735. Pubmedid: 25354106.
  • Peker D, Padron E, Bennett JM, Zhang X, Horna P, Epling-Burnette PK, Lancet JE, Pinilla-Ibarz J, Moscinski L, List AF, Komrokji RS, Zhang L. A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution. Acta Haematol. 2014 Nov;133(2):249-256. Pubmedid: 25413011.
  • List AF, Bennett JM, Sekeres MA, Skikne B, Fu T, Shammo JM, Nimer SD, Knight RD, Giagounidis A. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. Leukemia. 2014 May;28(5):1033-1040. Pubmedid: 24150217. Pmcid: PMC4017258.
  • Padron E, Komrokji R, List AF. The clinical management of chronic myelomonocytic leukemia. Clin Adv Hematol Oncol. 2014 Mar;12(3):172-178. Pubmedid: 24927265.
  • Steensma DP, Komrokji RS, Stone RM, List AF, Garcia-Manero G, Huber JM, Dennison B, Sekeres MA. Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes. Cancer. 2014 Jun;120(11):1670-1676. Pubmedid: 24577838.
  • Padron E, Yoder S, Kunigal S, Mesa T, Teer JK, Al Ali N, Sekeres MA, Painter JS, Zhang L, Lancet J, Maciejewski JP, Epling-Burnette PK, Sotomayor E, Komrokji RS, List AF. ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood. 2014 Jun;123(23):3675-3677. Pubmedid: 24904105. Pmcid: PMC4047502.
  • Nishihori T, Perkins J, Mishra A, Komrokji R, Kim J, Kharfan-Dabaja MA, Perez L, Lancet J, Fernandez H, List A, Anasetti C, Field T. Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome. Biol Blood Marrow Tr. 2014 Jun;20(6):776-780. Pubmedid: 24534108.
  • Keerthivasan G, Mei Y, Zhao B, Zhang L, Harris CE, Gao J, Basiorka AA, Schipma MJ, McElherne J, Yang J, Verma AK, Pellagatti A, Boultwood J, List AF, Williams DA, Ji P. Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS. Blood. 2014 Jul;124(5):780-790. Pubmedid: 24891322. Pmcid: PMC4118486.
  • Komrokji RS, Mailloux AW, Chen DT, Sekeres MA, Paquette R, Fulp WJ, Sugimori C, Paleveda-Pena J, Maciejewski JP, List AF, Epling-Burnette PK. A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction. Haematologica. 2014 Jul;99(7):1176-1183. Pubmedid: 24488560. Pmcid: PMC4077078.
  • Giagounidis A, Mufti GJ, Fenaux P, Germing U, List A, Macbeth KJ. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. Ann Hematol. 2014 Jan;93(1):1-11. Pubmedid: 24018623. Pmcid: PMC3889654.
  • Cogle CR, Iannacone MR, Yu D, Cole AL, Imanirad I, Yan L, Mackinnon JA, List AF, Rollison DE. High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment. Leuk Res. 2014 Jan;38(1):71-75. Pubmedid: 24280283.
  • Fenaux P, Seymour JF, Santini V, Silverman L, Gore S, List A, Sanz G, Mufti GJ, Estey E, Swern AS, Beach CL, Hellstrom-Lindberg E. Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model. Leuk Res. 2014 Feb;38(2):258-262. Pubmedid: 24360612.
  • Santini V, Prebet T, Fenaux P, Gattermann N, Nilsson L, Pfeilstöcker M, Vyas P, List AF. Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. Leuk Res. 2014 Dec;38(12):1381-1391. Pubmedid: 25444075.
  • Sekeres MA, Swern AS, Fenaux P, Greenberg PL, Sanz GF, Bennett JM, Dreyfus F, List AF, Li JS, Sugrue MM. Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q). Blood Cancer J. 2014 Aug;4:e242. Pubmedid: 25171203.
  • Komrokji RS, Padron E, Yu D, Fulp WJ, Rodriguez Y, Tinsley S, List AF, Lancet JE. Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes. Am J Hematol. 2014 Aug;89(8):809-812. Pubmedid: 24764152. Pmcid: PMC4561860.
  • Seymour JF, Bennett JM, List AF, Mufti GJ, Gore SD, Fenaux P, Santini V, Hetzer J, Songer S, Skikne BS, Beach CL. Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes. Brit J Haematol. 2014 Apr;165(1):49-56. Pubmedid: 24467613.
  • Jaglal MV, Duong VH, Bello CM, Al Ali NH, Padron E, Fernandez HF, List AF, Lancet JE, Komrokji RS. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. Leuk Res. 2014 Apr;38(4):443-446. Pubmedid: 24439565.
  • Sallman DA, Wei S, List A. PP2A: The Achilles Heal in MDS with 5q Deletion. Front Oncol. 2014;4:264. Pubmedid: 25295231. Pmcid: PMC4172014.
  • McGraw KL, Basiorka AA, Johnson JO, Clark J, Caceres G, Padron E, Heaton R, Ozawa Y, Wei S, Sokol L, List AF. Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors. PLoS One. 2014;9(12):e114249. Pubmedid: 25469886. Pmcid: PMC4254997.
  • Komrokji RS, Padron E, Lancet JE, List AF. Prognostic factors and risk models in myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2:S295-S299. Pubmedid: 24290214.
  • Caceres G, McGraw K, Yip BH, Pellagatti A, Johnson J, Zhang L, Liu K, Zhang LM, Fulp WJ, Lee JH, Al Ali NH, Basiorka A, Smith LJ, Daugherty FJ, Littleton N, Wells RA, Sokol L, Wei S, Komrokji RS, Boultwood J, List AF. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proc Natl Acad Sci U S A. 2013 Oct;110(40):16127-16132. Pubmedid: 24043769. Pmcid: PMC3791697.
  • Ostronoff F, Othus M, Kantarjian HM, Meshinchi S, Ravandi F, Hendrie PC, Faderl S, Becker PS, Cortes JE, Pagel JM, Petersdorf SH, Godwin JE, Willman CL, Pierce SA, List AF, Sandhu RK, Walter RB, Stirewalt DL, Appelbaum FR, Estey EH. A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia. Brit J Haematol. 2013 Oct;163(1):130-132. Pubmedid: 23829510. Pmcid: PMC4128010.
  • Jerez A, Clemente MJ, Makishima H, Rajala H, Gómez-Seguí I, Olson T, McGraw K, Przychodzen B, Kulasekararaj A, Afable M, Husseinzadeh HD, Hosono N, Leblanc F, Lagström S, Zhang D, Ellonen P, Tichelli A, Nissen C, Lichtin AE, Wodnar-Filipowicz A, Mufti GJ, List AF, Mustjoki S, Loughran TP, Maciejewski JP. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood. 2013 Oct;122(14):2453-2459. Pubmedid: 23926297. Pmcid: PMC3790512.
  • Duong VH, Padron E, List AF, Komrokji RS. Multikinase inhibitors for treating high-risk myelodysplastic syndromes: can this be brought into clinical practice?. Expert Rev Hematol. 2013 Oct;6(5):485-487. Pubmedid: 24083503.
  • Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, Sebti S, Kantarjian HM, Ravandi F, Lancet JE. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leuk Res. 2013 Nov;37(11):1461-1467. Pubmedid: 23993427. Pmcid: PMC4205589.
  • Chen X, Eksioglu EA, Zhou J, Zhang L, Djeu J, Fortenbery N, Epling-Burnette P, Van Bijnen S, Dolstra H, Cannon J, Youn JI, Donatelli SS, Qin D, De Witte T, Tao J, Wang H, Cheng P, Gabrilovich DI, List A, Wei S. Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest. 2013 Nov;123(11):4595-4611. Pubmedid: 24216507. Pmcid: PMC3809779.
  • Duong VH, Lancet JE, Alrawi E, Al-Ali NH, Perkins J, Field T, Epling-Burnette PK, Zhang L, List AF, Komrokji RS. Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models. Leuk Res. 2013 May;37(5):510-515. Pubmedid: 23332452.
  • Duong VH, Jaglal MV, Zhang L, Kale V, Lancet JE, Komrokji RS, List AF. Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy. Leuk Res. 2013 Mar;37(3):300-304. Pubmedid: 23273539.
  • Venner CP, Woltosz JW, Nevill TJ, Deeg HJ, Caceres G, Platzbecker U, Scott BL, Sokol L, Sung S, List AF, Karsan A. Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome. Haematologica. 2013 Mar;98(3):409-413. Pubmedid: 22929976. Pmcid: PMC3659949.
  • Adès L, Sekeres MA, Wolfromm A, Teichman ML, Tiu RV, Itzykson R, Maciejewski JP, Dreyfus F, List AF, Fenaux P, Komrokji RS. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res. 2013 Jun;37(6):609-613. Pubmedid: 23415110.
  • Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013 Jun;121(25):5068-5077. Pubmedid: 23632888. Pmcid: PMC4347259.
  • Khan SN, Jankowska AM, Mahfouz R, Dunbar AJ, Sugimoto Y, Hosono N, Hu Z, Cheriyath V, Vatolin S, Przychodzen B, Reu FJ, Saunthararajah Y, O'Keefe C, Sekeres MA, List AF, Moliterno AR, McDevitt MA, Maciejewski JP, Makishima H. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia. 2013 Jun;27(6):1301-1309. Pubmedid: 23486531.
  • Gore SD, Fenaux P, Santini V, Bennett JM, Silverman LR, Seymour JF, Hellstrom-Lindberg E, Swern AS, Beach CL, List AF. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica. 2013 Jul;98(7):1067-1072. Pubmedid: 23585522. Pmcid: PMC3696610.
  • Mishra A, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF, Komrokji RS. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Am J Hematol. 2013 Jul;88(7):566-570. Pubmedid: 23605934. Pmcid: PMC4685468.
  • Zhang L, Sotomayor EM, Papenhausen PR, Shao H, Moscinski LC, Sandin RL, Caceres G, Valenica H, Malafa M, List AF, Sokol L. Unusual concurrence of T-cell large granular lymphocytic leukemia with Franklin disease (gamma heavy chain disease) manifested with massive splenomegaly. Leuk Lymphoma. 2013 Jan;54(1):205-208. Pubmedid: 22694793.
  • Kar SA, Jankowska AM, Makishima H, Visconte V, Jerez A, Sugimoto Y, Muramatsu H, Traina F, Afable M, Guinta K, Tiu RV, Przychodzen B, Sakaguchi H, Kojima S, Sekeres MA, List AF, McDevitt MA, Maciejewski JP. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica. 2013 Jan;98(1):107-113. Pubmedid: 22773603. Pmcid: PMC3533671.
  • Griner LN, McGraw KL, Johnson JO, List AF, Reuther GW. JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth. Brit J Haematol. 2013 Jan;160(2):177-187. Pubmedid: 23157224. Pmcid: PMC4505927.
  • Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J, Caceres G, Billingsley D, Sokol L, Lancet J, Fortenbery N, Zhou J, Eksioglu EA, Sallman D, Wang H, Epling-Burnette PK, Djeu J, Sekeres M, Maciejewski JP, List A. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene. 2013 Feb;32(9):1110-1120. Pubmedid: 22525275. Pmcid: PMC3751397.
  • Trimaldi J, Carballido EM, Bowers JW, Anguiano AL, Zhang ZJ, Shah BD, Bruno S, List AF, Moscinski LC, Grady T, Agosti SJ, Kang L, Zhang L. B-lymphoblastic leukemia/lymphoma associated with t(8;13)(p11;q12)/ ZMYM2 (ZNF198)-FGFR1 : rare case and review of the literature. Acta Haematol. 2013 Dec;130(3):127-134. Pubmedid: 23594707.
  • Duong VH, Lin K, Reljic T, Kumar A, Al Ali NH, Lancet JE, List AF, Komrokji RS. Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):711-715. Pubmedid: 24054159.
  • Komrokji RS, Padron E, Ebert BL, List AF. Deletion 5q MDS: molecular and therapeutic implications. Best Pract Res Clin Haematol. 2013 Dec;26(4):365-375. Pubmedid: 24507813.
  • Komrokji RS, Raza A, Lancet JE, Ren C, Taft D, Maniar M, Wilhelm F, List AF. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. Brit J Haematol. 2013 Aug;162(4):517-524. Pubmedid: 23789936. Pmcid: PMC4685467.
  • Yang L, Mailloux A, Rollison DE, Painter JS, Maciejewski J, Paquette RL, Loughran TP, McGraw K, Makishima H, Radhakrishnan R, Wei S, Ren X, Komrokji R, List AF, Epling-Burnette PK. Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency. Leukemia. 2013 Apr;27(4):897-906. Pubmedid: 23072779. Pmcid: PMC4346223.
  • Bhagat TD, Zhou L, Sokol L, Kessel R, Caceres G, Gundabolu K, Tamari R, Gordon S, Mantzaris I, Jodlowski T, Yu Y, Jing X, Polineni R, Bhatia K, Pellagatti A, Boultwood J, Kambhampati S, Steidl U, Stein C, Ju W, Liu G, Kenny P, List A, Bitzer M, Verma A. miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling. Blood. 2013 Apr;121(15):2875-2881. Pubmedid: 23390194. Pmcid: PMC3624935.
  • Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF. Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia. 2013 Apr;27(4):977-980. Pubmedid: 23032694.
  • Kuendgen A, Lauseker M, List AF, Fenaux P, Giagounidis AA, Brandenburg NA, Backstrom J, Glasmacher A, Hasford J, Germing U. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia. 2013 Apr;27(5):1072-1079. Pubmedid: 23257782. Pmcid: PMC3650492.
  • Pogosova-Agadjanyan EL, Kopecky KJ, Ostronoff F, Appelbaum FR, Godwin J, Lee H, List AF, May JJ, Oehler VG, Petersdorf S, Pogosov GL, Radich JP, Willman CL, Meshinchi S, Stirewalt DL. The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemia. PLoS One. 2013;8(8):e70812. Pubmedid: 23967110. Pmcid: PMC3743845.
  • Mailloux AW, Sugimori C, Komrokji RS, Yang L, Maciejewski JP, Sekeres MA, Paquette R, Loughran TP, List AF, Epling-Burnette PK. Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol. 2012 Sep;189(6):3198-3208. Pubmedid: 22875800. Pmcid: PMC3436939.
  • Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C, Tamari R, Yu Y, Bhagat TD, Bhattacharyya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boultwood J, Montagna C, Silverman L, Maciejewski J, Greally JM, Ye BH, List AF, Steidl C, Steidl U, Verma A. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood. 2012 Sep;120(10):2076-2086. Pubmedid: 22753872. Pmcid: PMC3437595.
  • Komrokji RS, Lancet JE, Swern AS, Chen N, Paleveda J, Lush R, Saba HI, List AF. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood. 2012 Oct;120(17):3419-3424. Pubmedid: 22936658.
  • Komrokji RS, Verstovsek S, Padron E, List AF. Advances in the management of myelofibrosis. Cancer Control. 2012 Oct;19(4 Suppl):4-15. Pubmedid: 23042420.
  • Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K, Olson T, Przychodzen B, Afable M, Gomez-Segui I, Guinta K, Durkin L, Hsi ED, McGraw K, Zhang D, Wlodarski MW, Porkka K, Sekeres MA, List A, Mustjoki S, Loughran TP, Maciejewski JP. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012 Oct;120(15):3048-3057. Pubmedid: 22859607. Pmcid: PMC3471515.
  • Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol. 2012 Nov;87(11):1006-1009. Pubmedid: 23090887.
  • Nyland SB, Krissinger DJ, Clemente MJ, Irby RB, Baab KT, Jarbadan NR, Sokol L, Schaefer E, Liao J, Cuthbertson D, Epling-Burnette P, Paquette R, List AF, Maciejewski JP, Loughran TP. Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study. Leuk Res. 2012 May;36(5):581-587. Pubmedid: 22386729. Pmcid: PMC3312981.
  • Komrokji RS, Corrales-Yepez M, Al Ali N, Kharfan-Dabaja M, Padron E, Fields T, Lancet JE, List AF. Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome. Cancer. 2012 May;118(10):2659-2664. Pubmedid: 21956402.
  • Sugimoto Y, Sekeres MA, Makishima H, Traina F, Visconte V, Jankowska A, Jerez A, Szpurka H, O'Keefe CL, Guinta K, Afable M, Tiu R, McGraw KL, List AF, Maciejewski J. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. J Hematol Oncol. 2012 Mar;5:4. Pubmedid: 22390313. Pmcid: PMC3323440.
  • Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang L, Tiu R, O'Keefe CL, Afable M, Clemente M, Lee JM, Maciejewski JP, List AF, Epling-Burnette PK, Araten DJ. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. Blood Cancer J. 2012 Mar;2(3):e63. Pubmedid: 22829258. Pmcid: PMC3317526.
  • Craig BM, Rollison DE, List AF, Cogle CR. Underreporting of myeloid malignancies by United States cancer registries. Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):474-481. Pubmedid: 22237987. Pmcid: PMC3662977.
  • Komrokji RS, List AF. Lenalidomide for treatment of myelodysplastic syndromes. Curr Pharm Des. 2012 Jun;18(22):3198-3203. Pubmedid: 22571699.
  • List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, Paley C, Feigert J, Besa E. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol. 2012 Jun;30(17):2134-2139. Pubmedid: 22547607.
  • Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychodzen B, Visconte V, Tiu RV, O'Keefe CL, Mohamedali AM, Kulasekararaj AG, Pellagatti A, McGraw K, Muramatsu H, Moliterno AR, Sekeres MA, McDevitt MA, Kojima S, List A, Boultwood J, Mufti GJ, Maciejewski JP. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood. 2012 Jun;119(25):6109-6117. Pubmedid: 22553315. Pmcid: PMC3383019.
  • McDaniel JM, Zou JX, Fulp W, Chen DT, List AF, Epling-Burnette PK. Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation. Leukemia. 2012 Jun;26(6):1425-1429. Pubmedid: 22193963. Pmcid: PMC3321111.
  • Mathew RA, Bennett JM, Liu JJ, Komrokji RS, Lancet JE, Naghashpour M, Messina JL, List AF, Moscinski LC, Zhang L. Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature. Leuk Res. 2012 Jan;36(1):72-80. Pubmedid: 21782240.
  • List AF. New therapeutics for myelodysplastic syndromes. Leuk Res. 2012 Dec;36(12):1470-1474. Pubmedid: 22959510.
  • Epling-Burnette PK, McDaniel J, Wei S, List AF. Emerging immunosuppressive drugs in myelodysplastic syndromes. Expert Opin Emerg Drugs. 2012 Dec;17(4):519-541. Pubmedid: 23163589.
  • Sekeres MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List AF, Maciejewski JP. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood. 2012 Dec;120(25):4945-4951. Pubmedid: 22915641. Pmcid: PMC3525020.
  • Caceres G, Robey RW, Sokol L, McGraw KL, Clark J, Lawrence NJ, Sebti SM, Wiese M, List AF. HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1. Cancer Res. 2012 Aug;72(16):4204-4213. Pubmedid: 22761337. Pmcid: PMC4557794.
  • McGraw KL, Fuhler GM, Johnson JO, Clark JA, Caceres GC, Sokol L, List AF. Erythropoietin receptor signaling is membrane raft dependent. PLoS One. 2012 Aug;7(4):e34477. Pubmedid: 22509308. Pmcid: PMC3317978.
  • Raza A, Galili N, Smith SE, Godwin J, Boccia RV, Myint H, Mahadevan D, Mulford D, Rarick M, Brown GL, Schaar D, Faderl S, Komrokji RS, List AF, Sekeres M. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. Cancer. 2012 Apr;118(8):2138-2147. Pubmedid: 21887679.
  • Duong VH, Komrokji RS, List AF. Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion. Ther Adv Hematol. 2012 Apr;3(2):105-116. Pubmedid: 23556117. Pmcid: PMC3573434.
  • Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, Visconte V, Sugimoto Y, Prince C, O'Keefe C, Hsi ED, List A, Sekeres MA, Rao A, McDevitt MA, Maciejewski JP. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 2011 Oct;118(14):3932-3941. Pubmedid: 21828135. Pmcid: PMC3193268.
  • Komrokji RS, List AF. Role of lenalidomide in the treatment of myelodysplastic syndromes. Semin Oncol. 2011 Oct;38(5):648-657. Pubmedid: 21943671.
  • Sekeres MA, Maciejewski JP, List AF, Steensma DP, Artz A, Swern AS, Scribner P, Huber J, Stone R. Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey. Oncologist. 2011 Oct;16(6):904-911. Pubmedid: 21478277. Pmcid: PMC3228221.
  • Craig BM, Rollison DE, List AF, Cogle CR. Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes. Leuk Res. 2011 Nov;35(11):1453-1456. Pubmedid: 21851978. Pmcid: PMC3191243.
  • Ortega J, Komrokji R, List AF. The hematopoietic growth factors in the myelodysplastic syndromes. Cancer Treat Res. 2011 Nov;157:363-382. Pubmedid: 21052966.
  • Zhang L, Bennett JM, Zhang X, Moscinski L, Ibarz-Pinilla J, List AF, Komrokji R. Uncommon of the uncommon: low-grade myelodysplastic syndrome evolving into chronic myelogenous leukemia. J Clin Oncol. 2011 May;29(15):e434-e436. Pubmedid: 21149648.
  • Kharfan-Dabaja MA, Chavez JC, Yu D, Zhu W, Fernandez-Vertiz EI, Perkins J, Shapiro J, Bookout R, Perez L, Fernandez HF, Komrokji RS, Lancetf J, Brand L, Field T, Ayala E, Janssen W, List AF, Anasetti C. Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Tr. 2011 Mar;17(3):384-393. Pubmedid: 20655389.
  • Price SL, Lancet JE, George TJ, Wetzstein GA, List AF, Ho VQ, Fernandez HF, Pinilla-Ibarz J, Kharfan-Dabaja MA, Komrokji RS. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res. 2011 Mar;35(3):301-304. Pubmedid: 21109304.
  • Feldman EJ, Lancet JE, Kolitz JE, Ritchie EK, Roboz GJ, List AF, Allen SL, Asatiani E, Mayer LD, Swenson C, Louie AC. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol. 2011 Mar;29(8):979-985. Pubmedid: 21282541. Pmcid: PMC4520927.
  • Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellström-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer. 2011 Jun;117(12):2697-2702. Pubmedid: 21656747. Pmcid: PMC4000012.
  • Komrokji RS, Sekeres MA, List AF. Management of lower-risk myelodysplastic syndromes: the art and evidence. Curr Hematol Malig Rep. 2011 Jun;6(2):145-153. Pubmedid: 21442178.
  • Cogle CR, Craig BM, Rollison DE, List AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011 Jun;117(26):7121-7125. Pubmedid: 21531980. Pmcid: PMC3143554.
  • Sekeres MA, Gundacker H, Lancet J, Advani A, Petersdorf S, Liesveld J, Mulford D, Norwood T, Willman CL, Appelbaum FR, List AF. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood. 2011 Jul;118(3):523-528. Pubmedid: 21551228. Pmcid: PMC3142897.
  • Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellström-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer. 2011 Jan. Pubmedid: 21225870.
  • Sekeres MA, O'Keefe C, List AF, Paulic K, Afable M, Englehaupt R, Maciejewski JP. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. Am J Hematol. 2011 Jan;86(1):102-103. Pubmedid: 21080340.
  • Padron E, Komrokji R, List AF. Biology and treatment of the 5q- syndrome. Expert Rev Hematol. 2011 Feb;4(1):61-69. Pubmedid: 21322779.
  • Zhou L, McMahon C, Bhagat T, Alencar C, Yu Y, Fazzari M, Sohal D, Heuck C, Gundabolu K, Ng C, Mo Y, Shen W, Wickrema A, Kong G, Friedman E, Sokol L, Mantzaris I, Mantzaris G, Pellagatti A, Boultwood J, Platanias LC, Steidl U, Yan L, Yingling JM, Lahn MM, List A, Bitzer M, Verma A. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res. 2011 Feb;71(3):955-963. Pubmedid: 21189329. Pmcid: PMC3032816.
  • Lancet JE, Ravandi F, Ricklis RM, Cripe LD, Kantarjian HM, Giles FJ, List AF, Chen T, Allen RS, Fox JA, Michelson GC, Karp JE. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia. 2011 Dec;25(12):1808-1814. Pubmedid: 21760592. Pmcid: PMC4576993.
  • Padron E, Komrokji R, List AF. The 5q- syndrome: biology and treatment. CURR TREAT OPTION ON. 2011 Dec;12(4):354-368. Pubmedid: 21964863.
  • Rollison DE, Epling-Burnette PK, Park JY, Lee JH, Park H, Jonathan K, Cole AL, Painter JS, Guerrier M, Meléndez-Santiago J, Fulp W, Komrokji R, Lancet J, List AF. Telomere length in myelodysplastic syndromes. Leuk Lymphoma. 2011 Aug;52(8):1528-1536. Pubmedid: 21635204. Pmcid: PMC4350661.
  • Bello C, Yu D, Komrokji RS, Zhu W, Wetzstein GA, List AF, Lancet JE. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer. 2011 Apr;117(7):1463-1469. Pubmedid: 21425147. Pmcid: PMC4545502.
  • Tiu RV, Gondek LP, O'Keefe CL, Elson P, Huh J, Mohamedali A, Kulasekararaj A, Advani AS, Paquette R, List AF, Sekeres MA, McDevitt MA, Mufti GJ, Maciejewski JP. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood. 2011 Apr;117(17):4552-4560. Pubmedid: 21285439. Pmcid: PMC3099573.
  • Sokol L, Caceres G, Volinia S, Alder H, Nuovo GJ, Liu CG, McGraw K, Clark JA, Sigua CA, Chen DT, Moscinski L, Croce CM, List AF. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Brit J Haematol. 2011 Apr;153(1):24-32. Pubmedid: 21332710. Pmcid: PMC4294220.
  • Tehranchi R, Woll PS, Anderson K, Buza-Vidas N, Mizukami T, Mead AJ, Astrand-Grundström I, Strömbeck B, Horvat A, Ferry H, Dhanda RS, Hast R, Rydén T, Vyas P, Göhring G, Schlegelberger B, Johansson B, Hellström-Lindberg E, List A, Nilsson L, Jacobsen SE. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med. 2010 Sep;363(11):1025-1037. Pubmedid: 20825315.
  • Makishima H, Jankowska AM, Tiu RV, Szpurka H, Sugimoto Y, Hu Z, Saunthararajah Y, Guinta K, Keddache MA, Putnam P, Sekeres MA, Moliterno AR, List AF, McDevitt MA, Maciejewski JP. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia. 2010 Oct;24(10):1799-1804. Pubmedid: 20724984.
  • Sekeres MA, List AF, Cuthbertson D, Paquette R, Ganetzky R, Ganetsky R, Latham D, Paulic K, Afable M, Saba HI, Loughran TP, Maciejewski JP. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol. 2010 May;28(13):2253-2258. Pubmedid: 20354132. Pmcid: PMC2860439.
  • List A. Deciphering the path ahead in myelodysplastic syndrome. Am J Hematol. 2010 Mar;85(3):157-158. Pubmedid: 20143403.
  • Sokol L, Caceres G, Rocha K, Stockero KJ, Dewald DW, List AF. JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones. Leuk Res. 2010 Jun;34(6):821-823. Pubmedid: 19819015.
  • Chauncey TR, Gundacker H, Shadman M, List AF, Dakhil SR, Erba HP, Slovak ML, Chen IM, Willman CL, Kopecky KJ, Appelbaum FR. Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. Brit J Haematol. 2010 Jan;148(1):48-58. Pubmedid: 19821823. Pmcid: PMC2967366.
  • List AF. Iron overload in myelodysplastic syndromes: diagnosis and management. Cancer Control. 2010 Jan;17 Suppl:2-8. Pubmedid: 20125080.
  • Komrokji RS, Lancet JE, List AF. Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?. Curr Hematol Malig Rep. 2010 Jan;5(1):9-14. Pubmedid: 20425391.
  • Komrokji RS, Matacia-Murphy GM, Al Ali NH, Beg MS, Safa MM, Rollison DE, List AF. Outcome of patients with myelodysplastic syndromes in the Veterans Administration population. Leuk Res. 2010 Jan;34(1):59-62. Pubmedid: 19368972.
  • Pal R, Monaghan SA, Hassett AC, Mapara MY, Schafer P, Roodman GD, Ragni MV, Moscinski L, List A, Lentzsch S. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood. 2010 Jan;115(3):605-614. Pubmedid: 19965623.
  • Sugimori C, List AF, Epling-Burnette PK. Immune dysregulation in myelodysplastic syndrome. Hematol Rep. 2010 Jan;2(1):e1. Pubmedid: 22184512. Pmcid: PMC3222262.
  • Kumar A, List AF, Hozo I, Komrokji R, Djulbegovic B. Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis. Haematologica. 2010 Feb;95(2):340-342. Pubmedid: 19850902. Pmcid: PMC2817042.
  • Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E, Fernandez HF, Janssen W, Lancet J, Perez L, Sullivan D, List A, Anasetti C. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010 Feb;45(2):255-260. Pubmedid: 19543327.
  • Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010 Feb;28(4):562-569. Pubmedid: 20026804.
  • Seymour JF, Fenaux P, Silverman LR, Mufti GJ, Hellström-Lindberg E, Santini V, List AF, Gore SD, Backstrom J, McKenzie D, Beach CL. Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol. 2010 Dec;76(3):218-227. Pubmedid: 20451404. Pmcid: PMC4000027.
  • Santini V, Fenaux P, Mufti GJ, Hellström-Lindberg E, Silverman LR, List A, Gore SD, Seymour JF, Backstrom J, Beach CL. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. Eur J Haematol. 2010 Aug;85(2):130-138. Pubmedid: 20394651. Pmcid: PMC4000014.
  • Komrokji RS, List AF. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions. Hematol Oncol Clin North Am. 2010 Apr;24(2):377-388. Pubmedid: 20359632.
  • Fenaux P, Gattermann N, Seymour JF, Hellström-Lindberg E, Mufti GJ, Duehrsen U, Gore SD, Ramos F, Beyne-Rauzy O, List A, McKenzie D, Backstrom J, Beach CL. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Brit J Haematol. 2010 Apr;149(2):244-249. Pubmedid: 20136825. Pmcid: PMC4000023.
  • Epling-Burnette PK, List AF. Advancements in the molecular pathogenesis of myelodysplastic syndrome. Curr Opin Hematol. 2009 Mar;16(2):70-76. Pubmedid: 19468267.
  • Kurtin SE, List AF. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide. Clin Lymphoma Myeloma. 2009 Jun;9(3):E10-E13. Pubmedid: 19525184.
  • Raza A, Galili N, Smith S, Godwin J, Lancet J, Melchert M, Jones M, Keck JG, Meng L, Brown GL, List A. Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Blood. 2009 Jun;113(26):6533-6540. Pubmedid: 19398716.
  • Kiss R, Polgár T, Kirabo A, Sayyah J, Figueroa NC, List AF, Sokol L, Zuckerman KS, Gali M, Bisht KS, Sayeski PP, Keseru GM. Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. Bioorg Med Chem Lett. 2009 Jul;19(13):3598-3601. Pubmedid: 19447617. Pmcid: PMC2812898.
  • Zou JX, Rollison DE, Boulware D, Chen DT, Sloand EM, Pfannes LV, Goronzy JJ, Bai F, Painter JS, Wei S, Cosgrove D, List AF, Epling-Burnette PK. Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome. Leukemia. 2009 Jul;23(7):1288-1296. Pubmedid: 19282834. Pmcid: PMC3252820.
  • Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J, Muramatsu H, O'Keefe C, Hsi E, Paquette RL, Kojima S, List AF, Sekeres MA, McDevitt MA, Maciejewski JP. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol. 2009 Dec;27(36):6109-6116. Pubmedid: 19901108. Pmcid: PMC3040009.
  • Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, Byrd J, Sokol L, Lawrence N, Pireddu R, Dewald G, Williams A, Maciejewski J, List A. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A. 2009 Aug;106(31):12974-12979. Pubmedid: 19470455. Pmcid: PMC2722346.
  • Lancet JE, Baer MR, Duran GE, List AF, Fielding R, Marcelletti JF, Multani PS, Sikic BI. A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. Leuk Res. 2009 Aug;33(8):1055-1061. Pubmedid: 19108889.
  • Szende A, Schaefer C, Goss TF, Heptinstall K, Knight R, Lübbert M, Deschler B, Fenaux P, Mufti GJ, Killick S, List AF. Valuation of transfusion-free living in MDS: results of health utility interviews with patients. Health Qual Life Outcomes. 2009;7:81-. Pubmedid: 19737399. Pmcid: PMC2746210.
  • List A. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes. Clin Lymphoma Myeloma. 2009;9 Suppl 3:S302-S304. Pubmedid: 19778857.
  • Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, List A, Fenaux P, Sanz G, Issa JP, Freireich EJ, Garcia-Manero G. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008 Sep;113(6):1351-1361. Pubmedid: 18618511. Pmcid: PMC4188533.
  • Navas T, Zhou L, Estes M, Haghnazari E, Nguyen AN, Mo Y, Pahanish P, Mohindru M, Cao T, Higgins LS, Platanias LC, List A, Verma A, Bhagat T, Gajavelli S, Kambhampati S. Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Leuk Lymphoma. 2008 Oct;49(10):1963-1975. Pubmedid: 18949619. Pmcid: PMC2735641.
  • Zhou L, Nguyen AN, Sohal D, Ying Ma J, Pahanish P, Gundabolu K, Hayman J, Chubak A, Mo Y, Bhagat TD, Das B, Kapoun AM, Navas TA, Parmar S, Kambhampati S, Pellagatti A, Braunchweig I, Zhang Y, Wickrema A, Medicherla S, Boultwood J, Platanias LC, Higgins LS, List AF, Bitzer M, Verma A. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood. 2008 Oct;112(8):3434-3443. Pubmedid: 18474728. Pmcid: PMC2569182.
  • List AF. Treatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes. Cancer Control. 2008 Oct;15 Suppl:29-39. Pubmedid: 18813207.
  • Ozawa Y, Williams AH, Estes ML, Matsushita N, Boschelli F, Jove R, List AF. Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT). Leuk Res. 2008 Jun;32(6):893-903. Pubmedid: 18179820.
  • Rollison D, Howlader N, Smith M, Strom S, Merritt W, Ries L, Edwards B, List A. Epidemiology of Myelodysplastic Syndromes and Chronic Myeloproliferative Disorders in the United States, 2001-2004: Utilizing Data from the NAACCR and SEER Programs. Blood. 2008 Jul;112(1):45-52. Pubmedid: 18443215.
  • Melchert M, List A. Targeted therapies in myelodysplastic syndrome. Semin Hematol. 2008 Jan;45(1):31-38. Pubmedid: 18179967.
  • Raza A, Reeves J, Feldman E, Dewald G, Bennett J, Deeg H, Dreisbach L, Schiffer C, Stone R, Greenberg P, Curtin P, Klimek V, Shammo J, Thomas D, Knight R, Schmidt M, Wride K, Zeldis J, List A. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008 Jan;111(1):86-93. Pubmedid: 17893227.
  • Knop S, Einsele H, Bargou R, Cosgrove D, List A. Adjusted dose lenalidomide is safe and effective in patients with deletion (5q) myelodysplastic syndrome and severe renal impairment. Leuk Lymphoma. 2008 Feb;49(2):346-349. Pubmedid: 18231924.
  • Haferlach C, Bacher U, Tiu R, Maciejewski JP, List A. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing. Cancer Genet Cytogen. 2008 Dec;187(2):101-111. Pubmedid: 19027491.
  • Sekeres MA, Maciejewski JP, Giagounidis AA, Wride K, Knight R, Raza A, List AF. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2008 Dec;26(36):5943-5949. Pubmedid: 19018091. Pmcid: PMC2645116.
  • List A. Lenalidomide in myelodysplastic syndromes. Clin Adv Hematol Oncol. 2008 Apr;6(4):271-2, 311. Pubmedid: 18496493.
  • Melchert M, List A. The thalidomide saga. Int J Biochem Cell B. 2007 Oct;39(7-8):1489-1499. Pubmedid: 17369076.
  • Sokol L, List A. Immunomodulatory therapy for myelodysplastic syndromes. Int J Hematol. 2007 Nov;86(4):301-305. Pubmedid: 18055335.
  • Mohamedali A, Gaken J, Twine N, Ingram W, Westwood N, Lea N, Hayden J, Donaldson N, Aul C, Gattermann N, Giagounidis A, Germing U, List A, Mufti G. Prevalence and prognostic significance of allelic imbalance by single nucleotide polymorphism analysis in low risk myelodysplastic syndromes. Blood. 2007 Nov;110(9):3365-3373. Pubmedid: 17634407.
  • List A. Lenalidomide--the phoenix rises. N Engl J Med. 2007 Nov;357(21):2183-2186. Pubmedid: 18032768.
  • Ortega J, List A. Immunomodulatory drugs in the treatment of myelodysplastic syndromes. Curr Opin Oncol. 2007 Nov;19(6):656-659. Pubmedid: 17906467.
  • Melchert M, Kale V, List A. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes. Curr Opin Hematol. 2007 Mar;14(2):123-129. Pubmedid: 17255789.
  • Lancet JE, List AF, Moscinski LC. Treatment of deletion 5q acute myeloid leukemia with lenalidomide. Leukemia. 2007 Mar;21(3):586-588. Pubmedid: 17230228.
  • Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, ZouJ, Ku E, Zhong B, Boulware D, Moscinski L, Wei S, Djeu JY, List AF. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood. 2007 Jun;109(11):4816-4824. Pubmedid: 17341666. Pmcid: PMC1885518.
  • Melchert M, Williams C, List A. Remitting activity of lenalidomide in treatment-induced myelodysplastic syndrome. Leukemia. 2007 Jul;21(7):1576-1578. Pubmedid: 17392815.
  • Giles FJ, List AF, Carroll M, Cortes JE, Valickas J, Chen BL, Masson E, Jacques C, Laurent D, Albitar M, Feldman EJ, Roboz GJ. PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leuk Res. 2007 Jul;31(7):891-897. Pubmedid: 17560285.
  • Epling-Burnette PK, Painter JS, Rollison DE, Ku E, Vendron D, Widen R, Boulware D, Zou JX, Bai F, List AF. Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome. Leukemia. 2007 Apr;21(4):659-667. Pubmedid: 17301813.
  • Nam S, Williams A, Vultur A, List A, Bhalla K, Smith D, Lee FY, Jove R. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther. 2007 Apr;6(4):1400-1405. Pubmedid: 17431118.
  • Melchert M, List A. Management of RBC-transfusion dependence. Hematology Am Soc Hematol Educ Program. 2007;398-404. Pubmedid: 18024657.
  • Baker AF, Bellamy W, Tate WR, Bair WB, Heaton R, List AF. Suppressor of cytokine signaling-3 is overexpressed in erythroid precursors of myelodysplastic syndrome. Leukemia. 2006 Sep;20(9):1620-1621. Pubmedid: 16855630.
  • Kale V, List A. Immunomodulatory drugs (IMiDs): a new treatment option for myelodysplastic syndromes. Curr Pharm Biotechnol. 2006 Oct;7(5):339-342. Pubmedid: 17076650.
  • List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006 Oct;355(14):1456-1465. Pubmedid: 17021321.
  • Pabst T, Stillner E, Neuberg D, Nimer S, Willman C, List A, Melo J, Tenen DG, Mueller B. Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemia. Br J Haematol. 2006 May;133(4):400-402. Pubmedid: 16643447.
  • Sekeres MA, List A. Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: Is it any good?. Curr Hematol Malig Rep. 2006 Mar;1(1):16-19. Pubmedid: 20425326.
  • Roboz GJ, Giles FJ, List AF, Cortes JE, Carlin R, Kowalski M, Bilic S, Masson E, Rosamilia M, Schuster MW, Laurent D, Feldman EJ. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia. 2006 Jun;20(6):952-957. Pubmedid: 16617323.
  • Schiller G, Slack J, Hainsworth J, Mason J, Saleh M, Rizzieri D, Douer D, List A. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol. 2006 Jun;24(16):2456-2464. Pubmedid: 16651647.
  • Giles FJ, Bellamy WT, Estrov Z, O'Brien SM, Verstovsek S, Ravandi F, BeranM, Bycott P, Pithavala Y, Steinfeldt H, Reich SD, List AF, Yee KW. The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk Res. 2006 Jul;30(7):801-811. Pubmedid: 16332390.
  • Naing A, Sokol L, List A. Developmental therapeutics for myelodysplastic syndromes. J Natl Compr Canc Netw. 2006 Jan;4(1):78-82. Pubmedid: 16403406.
  • List A, Baker A, Green S, Bellamy W. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. Cancer Control. 2006 Dec;13 Suppl:4-11. Pubmedid: 17242661.
  • List A. Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes. Cancer Control. 2006 Dec;13 Suppl:12-16. Pubmedid: 17242662.
  • Navas TA, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P, Parmar S, Haghnazari E, Zhou L, Collins R, Kerr I, Nguyen AN, Xu Y, Platanias LC, List AF, Higgins LS, Verma A. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood. 2006 Dec;108(13):4170-4177. Pubmedid: 16940419. Pmcid: PMC1895446.
  • List A. Lenalidomide: from bench to bedside (part 1). Cancer Control. 2006 Dec;13 Suppl:2-3. Pubmedid: 17242660.
  • Goss TF, Szende A, Schaefer C, Totten PJ, Knight R, Jädersten M, Hellström-Lindberg E, List AF. Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States. Cancer Control. 2006 Dec;13 Suppl:17-25. Pubmedid: 17242663.
  • Crane E, List A. Lenalidomide: an immunomodulatory drug. Future Oncol. 2005 Oct;1(5):575-583. Pubmedid: 16556034.
  • Verma A, List A. Cytokine targets in the treatment of myelodysplastic syndromes. Curr Hematol Rep. 2005 Nov;4(6):429-435. Pubmedid: 16232378.
  • List A. New agents in the treatment of MDS. Clin Adv Hematol Oncol. 2005 Nov;3(11):832-834. Pubmedid: 16491623.
  • Steensma D, List A. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. Mayo Clin Proc. 2005 May;80(5):681-698. Pubmedid: 15887439.
  • Sekeres M, List A. Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good?. Curr Hematol Rep. 2005 May;4(3):182-185. Pubmedid: 15865869.
  • List A, Kurtin S, Roe D, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis J. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005 Feb;352(6):549-557. Pubmedid: 15703420.
  • Nakao S, Deeg HJ, Ishikawa T, Marsh J, List A, Tomonaga M. Myelodysplastic syndrome. Int J Hematol. 2005 Dec;82(5):412-416. Pubmedid: 16533744.
  • List A. Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS). Semin Oncol. 2005 Aug;32(4 Suppl 5):S31-S35. Pubmedid: 16085015.
  • List A. Introduction. Semin Oncol. 2005;32:1-2. Pubmedid: 16085010.
  • Crane E, List A. Immunomodulatory drugs. Cancer Invest. 2005;23(7):625-634. Pubmedid: 16305990.
  • Mahadevan D, List A. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood. 2004 Oct;104(7):1940-1951. Pubmedid: 15217827.
  • List AF, Glinsmann-Gibson B, Stadheim C, Meuillet EJ, Bellamy W, Powis G. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells. Exp Hematol. 2004 Jun;32(6):526-535. Pubmedid: 15183893.
  • Bhalla K, List A. Histone deacetylase inhibitors in myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004 Feb;17(4):595-611. Pubmedid: 15494297.
  • Nouzova M, Holtan N, Oshiro MM, Isett RB, Munoz-Rodriguez JL, List AF, Narro ML, Miller SJ, Merchant NC, Futscher BW. Epigenomic changes during leukemia cell differentiation: analysis of histone acetylation and cytosine methylation using CpG island microarrays. J Pharmacol Exp Ther. 2004 Dec;311(3):968-981. Pubmedid: 15302897.
  • List A, Vardiman J, Issa J, DeWitte T. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2004;297-317. Pubmedid: 15561689.
  • List A. New paradigm in the management of myelodysplastic syndromes. Cancer Control. 2004;11(6):2-2. Pubmedid: 15625529.
  • Mufti G, List A, Gore S, Ho A. Myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program. 2003;176-199. Pubmedid: 14633782.
  • Unger J, LeBlanc M, Crowley J, Grossman H, Natale R, Wozniak A, Berenson J, List A, Peters WA 3rd, Flanigan R, Macdonald J, Al-Sarraf M, Thompson I, Coltman CA J. Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture. J Clin Oncol. 2003;21:246s-252s. Pubmedid: 14645404.
  • List A, Kopecky K, Willman C, Head D, Slovak M, Douer D, Dakhil S, Appelbaum F. Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. Blood. 2002 Sep;100(5):1910-1912. Pubmedid: 12176916.
  • Quinones H, List A, Gerner E. Selective exclusion by the polyamine transporter as a mechanism for differential radioprotection of amifostine derivatives. Clin Cancer Res. 2002 May;8(5):1295-1300. Pubmedid: 12006551.
  • List A. New approaches to the treatment of myelodysplasia. Oncologist. 2002;7 Suppl 1:39-49. Pubmedid: 11961208.
  • Dodge J, Munson C, List A. KG-1 and KG-1a model the p15 CpG island methylation observed in acute myeloid leukemia patients. Leuk Res. 2001 Oct;25(10):917-925. Pubmedid: 11532526.
  • Dorr R, Karanes C, Spier C, Grogan T, Greer J, Moore J, Weinberger B, Schiller G, Pearce T, Litchman M, Dalton W, Roe D, List A. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J Clin Oncol. 2001 Mar;19(6):1589-1599. Pubmedid: 11250987.
  • List A, Kopecky K, William C, Head D, Persons D, Slovak M, Dorr R, Karanes C, Hynes H, Doroschow J, Shurafa M, Appelbaum F. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2001 Dec;98(12):3212-3220. Pubmedid: 11719356.
  • Bellamy W, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, Grogan T, List A. Vascular endothelial cell growth factor is an authocrine promoter of abnormal localized immature myeloid precursors and leukemia progentitor formation in myelodysplastic syndromes. Blood. 2001;97(5):1427-1434. Pubmedid: 11222390.
  • Klasa R, List A, Cheson B. Rational approaches to design of therapeutics targeting molecular markers. Hematology Am Soc Hematol Educ Program. 2001;443-462. Pubmedid: 11722998.
  • List A. Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies. Oncologist. 2001;6:24-31. Pubmedid: 11700389.
  • List AF, Maziarz R, Stiff P, Jansen J, Liesveld J, Andrews F, Schuster M, Wolff S, Litzow M, Karanes C, Dahlberg S, Kirkhart B, Bianco JA, Singer JW. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group. Bone Marrow Transplant. 2000 Feb;25(3):283-291. Pubmedid: 10673700.
  • List A, Gerner E. Amifostine: a tonic or toxin to myeloid progenitors. Leuk Res. 2000 Dec;24(12):1009-1011. Pubmedid: 11077114.
  • Rosenfeld C, List A. A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia. 2000;14(1):2-8. Pubmedid: 10637470.
  • Rimsza l, Kopecky K, Ruschulte J, Chen I, Slovak M, Karanes C, Godwin J, List A. Microsatellite instability is not a defining genetic feature of acute myeloid leukemogenesis in adults: results of a retrospective study of 132 patients and review of the literature. Leukemia. 2000;14(6):1044-1051. Pubmedid: 10865971.
  • Stiff P, Gingrich R, Luger S, Wyres M, Brown R, LeMaistre C, Perrry J, Schenkein D, List A, Mason J, Bensinger W, Wheeler C, Freter C, Parker W. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant. 2000;26(5):471-481. Pubmedid: 11019835.
  • List A. Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia. Semin Oncol. 1999 Apr;26(2 Suppl 7):61-65. Pubmedid: 10348262.
  • Miller A, Noyes W, Taetle R, List A. Limited erythropoietic response to combined treatment with recombinant human interleukim 3 and erythropoietin in myelodysplastic syndrome. Leuk Res. 1999;23(1):77-83. Pubmedid: 9933139.
  • List AF. Pharmacological differentiation and anti-apoptotic therapy in myelodysplastic syndromes. Forum (Genova). 1999;9(1):35-45. Pubmedid: 10101209.
  • List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL. Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors. Leukemia. 1998 Oct;12(10):1596-1602. Pubmedid: 9766505.
  • List AF. Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS?. Leuk Res. 1998 May;22 Suppl 1:S7-11. Pubmedid: 9734693.
  • Doll DC, Kasper LM, Taetle R, List AF. Treatment with low-dose oral etoposide in patients with myelodysplastic syndromes. Leuk Res. 1998 Jan;22(1):7-12. Pubmedid: 9585073.
  • Taylor CW, Wang LM, List AF, Fernandes D, Paine-Murrieta GD, Johnson CS, Capizzi RL. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. Eur J Cancer. 1997 Sep;33(10):1693-1698. Pubmedid: 9389935.
  • List AF, Brasfield F, Heaton R, Glinsmann-Gibson B, Crook L, Taetle R, Capizzi R. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood. 1997 Nov;90(9):3364-3369. Pubmedid: 9345018.
  • List AF. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia. 1996 Jun;10(6):937-942. Pubmedid: 8667648.
  • List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin Oncol. 1996 Aug;23(4 Suppl 8):58-63. Pubmedid: 8783669.
  • List AF. The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia. 1996 Apr;10 Suppl 1:S36-S38. Pubmedid: 8618469.
  • Kintzel PE, Rollins CJ, Yee WJ, List AF. Low itraconazole serum concentrations following administration of itraconazole suspension to critically ill allogeneic bone marrow transplant recipients. Ann Pharmacother. 1995 Feb;29(2):140-143. Pubmedid: 7756712.
  • Doll DC, Sun PC, List AF. Complete hematologic remission with oral etoposide in a patient with chronic myelomonocytic leukemia and profound dyserythropoiesis. Leuk Res. 1994 May;18(5):381-384. Pubmedid: 8182929.
  • Glinsmann-Gibson B, Spier C, Baier M, Taetle R, Broudy VC, List AF. Mast cell growth factor (c-kit ligand) restores growth of multipotent progenitors in myelodysplastic syndrome. Leukemia. 1994 May;8(5):827-832. Pubmedid: 7514248.
  • List AF, Spier CM, Miller TP, Grogan TM. Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence. Leukemia. 1993 Mar;7(3):398-403. Pubmedid: 7680400.
  • List AF, Doll DC. Alpha-interferon in the treatment of idiopathic myelofibrosis. Br J Haematol. 1992 Apr;80(4):566-567. Pubmedid: 1581246.
  • List AF, Spier CM, Cline A, Doll DC, Garewal H, Morgan R, Sandberg AA. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Brit J Haematol. 1991 May;78(1):28-34. Pubmedid: 1675116.
  • Kreisle WH, Alberts DS, List AF, McCloskey T, Plezia P, Peng YM, George M. A phase I trial of 14-day continuous intravenous infusion mitoxantrone. Anticancer Drugs. 1991 Jun;2(3):251-259. Pubmedid: 1802019.
  • Doll DC, Landreneau RJ, List AF. Malignant thymoma associated with peripheral T-cell lymphocytosis. Med Pediatr Oncol. 1991;19(6):496-498. Pubmedid: 1961136.
  • List AF, Kummet TD, Adams JD, Chun HG. Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate. Am J Med. 1990 Sep;89(3):388-390. Pubmedid: 1697447.
  • List AF, Kummet TD, Kerr DM. Acute myelofibrosis: response to recombinant human interferon alpha-2a. Leuk Res. 1990;14(4):321-326. Pubmedid: 2332985.
  • Doll DC, List AF, Dayhoff DA, Loy TS, Ringenberg QS, Yarbro JW. Acanthocytosis associated with myelodysplasia. J Clin Oncol. 1989 Oct;7(10):1569-1572. Pubmedid: 2778485.
  • Doll DC, List AF. Myelodysplastic syndromes. West J Med. 1989 Aug;151(2):161-167. Pubmedid: 2672599. Pmcid: PMC1026906.
  • Grote TH, Grosh WW, List AF, Wiley R, Cousar JB, Johnson DH. Primary lymphoma of the central nervous system. A report of 20 cases and a review of the literature. Am J Clin Oncol. 1989 Apr;12(2):93-100. Pubmedid: 2650529.
  • List AF, Doll DC. Thrombosis associated with procainamide-induced lupus anticoagulant. Acta Haematol. 1989;82(1):50-52. Pubmedid: 2505475.
  • List AF, Greer JP, Cousar JC, Stein RS, Johnson DH, Reynolds VH, Greco FA, Flexner JM, Hande KR. Non-Hodgkin's lymphoma of the gastrointestinal tract: an analysis of clinical and pathologic features affecting outcome. J Clin Oncol. 1988 Jul;6(7):1125-1133. Pubmedid: 3392561.
  • List AF, Beaird DH, Kummet T. Ranitidine-induced granulocytopenia: recurrence with cimetidine administration. Ann Intern Med. 1988 Apr;108(4):566-567. Pubmedid: 3348565.
  • Koop HO, Holodniy M, List AF. Fulminant Kaposi's sarcoma complicating long-term corticosteroid therapy. Am J Med. 1987 Oct;83(4):787-789. Pubmedid: 2823601.
  • List AF, Greco FA, Vogler LB. Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus. J Clin Oncol. 1987 Oct;5(10):1673-1689. Pubmedid: 2821199.
  • Doll DC, List AF, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med. 1986 Jul;105(1):48-51. Pubmedid: 2424354.
  • List AF, Hainsworth JD, Davis BW, Hande KR, Greco FA, Johnson DH. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin Oncol. 1986 Aug;4(8):1191-1198. Pubmedid: 3016206.
  • List AF, Doll DC, Greco FA. Lung cancer in Hodgkin's disease: association with previous radiotherapy. J Clin Oncol. 1985 Feb;3(2):215-221. Pubmedid: 2981984.
  • List AF, Greco FA. Lung cancer after exposure to radon daughters. N Engl J Med. 1984 Sep;311(13):858-859. Pubmedid: 6088981.
  • Doll DC, List AF. Burkitt's lymphoma in a homosexual. Lancet. 1982 May;1(8279):1026-1027. Pubmedid: 6122840.
  • List AF, Bartram SF, Nazar BL. Interactions of delta9-tetrahydrocannabinol, adrenal steroids, and ethanol. J Pharm Pharmacol. 1975 Aug;27(8):606-607. Pubmedid: 239177.
  • List A. Methyltransferase inhibitors: changing the treatment algorithm for myelodysplastic syndromes. Cancer Control. 11(6 Suppl):16-19. Pubmedid: 15625533.

Provider

Alan F. List, MD
President and CEO

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Malignant Hematology

Print Print Physician Bio

Participating Trials

CLINICAL TRIAL 14690
Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer
Condition: Cancer Control
Intervention:
Open

CLINICAL TRIAL 17929
A Phase I/II, Multicenter, Open-label, Dose Escalation and Randomized Trial of BI 836858 in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
Condition: Malignant Hematology
Intervention: BI 836858
Open

CLINICAL TRIAL 18390
A Phase 1 Dose Escalation, Multicenter, Open-Label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 In Patients With Relapsed or Refractory Hematologic Malignancies
Condition: Malignant Hematology
Intervention: FT-1101
Open

CLINICAL TRIAL 18762
An open-label, multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in adult patients with newly diagnosed Fms-like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia (AML) who are eligible for standard induction and consolidation chemotherapy
Condition: Malignant Hematology
Intervention: Cytarabine (Cytosine Arabinoside); Daunomycin (daunorubicin); Midostaurin; daunorubicin
Open

CLINICAL TRIAL 17865
SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
Condition: Malignant Hematology
Intervention: SL-401
Open

CLINICAL TRIAL 18674
A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myelogenous Leukemia
Condition: Malignant Hematology
Intervention: MLN4924 (Pevonedistat); Pevonedistat; azacitidine (5-azacitidine)
Open

CLINICAL TRIAL 18434
A Phase 1/2a study of E6201 for the treatment of advanced hematologic malignancies with FLT3 and/or Ras mutations, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML)
Condition: Malignant Hematology
Intervention: E6201
Open

CLINICAL TRIAL 18083
Phase II Randomized Study of Lower Doses of Decitabine (DAC; 20 mg/m^2 IV daily for 3 days every month) versus Azacitidine (AZA; 75 mg/m^2 SC/IV daily for 3 days every month) versus Azcitidine (AZA; 75 mg/m^2 SC/IV daily for 5 days every month) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Dependent versus Best Supportive Care (BSC) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Independent
Condition: Malignant Hematology
Intervention: azacitidine (5-azacitidine); decitabine (5-aza-2'-deoxycytidine)
Open

CLINICAL TRIAL 18815
A Phase 2 Study of Tipifarnib in Subjects with Chronic Myelomonocytic Leukemia
Condition: Malignant Hematology
Intervention: Zarnestra (tipifarnib); tipifarnib
Open

CLINICAL TRIAL 18876
A Phase 1/1b Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 alone and in Combination with Cytarabine (Ara-C) in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome with Wild-Type TP53
Condition: Malignant Hematology
Intervention: ALRN-6924; Cytarabine (Cytosine Arabinoside)
Open

CLINICAL TRIAL 18406
A Phase 1 Study of AZD1775 in Combination with Belinostat in Relapsed and Refractory Myeloid Malignancies and Selected Untreated Patients with Acute Myeloid Leukemia
Condition: Malignant Hematology
Intervention: AZD1775; Belinostat; MK-1775 (AZD1775); PXD101 (Belinostat)
Open

CLINICAL TRIAL 18610
A Phase I-II Study of Triciribine Phosphate Monohydrate (PTX-200) Plus Cytarabine in Refractory or Relapsed Acute Leukemia
Condition: Malignant Hematology
Intervention: Cytarabine (Cytosine Arabinoside); PTX-200; Triciribine Phosphate monohydrate (PTX-200)
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).


Provider

Alan F. List, MD
President and CEO

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Malignant Hematology

Print Print Physician Bio